Literature DB >> 19903418

Gastric acid hypersecretory states: recent insights and advances.

Nauramy Osefo1, Tetsuhide Ito, Robert T Jensen.   

Abstract

Gastric acid hypersecretory states are characterized by basal hypersecretion of gastric acid and historically include disorders associated with hypergastrinemia, hyperhistaminemia, and those of unknown etiology. Although gastric acid secretion is infrequently measured, it is important to recognize the role of gastric hypersecretion in the symptoms of these disorders because they share several features of pathogenesis and treatment. In this article, recent important articles reporting insights into their diagnosis, pathogenesis, and treatment are reviewed. Particular attention is paid to Zollinger-Ellison syndrome, because it has the most extreme acid hypersecretion of this group of disorders and because numerous recent articles deal with various aspects of the diagnosis, molecular pathogenesis, and treatment of the gastrinoma itself or the acid hypersecretion. Two new hypersecretory disorders are reviewed: rebound acid hypersecretion after the use of proton pump inhibitors and acid hypersecretion with cysteamine treatment in children with cystinosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903418      PMCID: PMC2792981          DOI: 10.1007/s11894-009-0067-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  64 in total

Review 1.  Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours.

Authors:  F Gibril; R T Jensen
Journal:  Dig Liver Dis       Date:  2004-02       Impact factor: 4.088

2.  Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.

Authors:  B I Hirschowitz; J Simmons; J Mohnen
Journal:  Aliment Pharmacol Ther       Date:  2001-11       Impact factor: 8.171

Review 3.  Gastrointestinal abnormalities and involvement in systemic mastocytosis.

Authors:  R T Jensen
Journal:  Hematol Oncol Clin North Am       Date:  2000-06       Impact factor: 3.722

4.  Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?

Authors:  V D Corleto; B Annibale; F Gibril; S Angeletti; J Serrano; D J Venzon; G Delle Fave; R T Jensen
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

Review 5.  Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature.

Authors:  P K Roy; D J Venzon; K M Feigenbaum; P D Koviack; S Bashir; J V Ojeaburu; F Gibril; R T Jensen
Journal:  Medicine (Baltimore)       Date:  2001-05       Impact factor: 1.889

6.  Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form.

Authors:  F Gibril; D J Venzon; J V Ojeaburu; S Bashir; R T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

Review 7.  Surgical treatment of sporadic gastrinoma.

Authors:  Kerstin Lorenz; Henning Dralle
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  Non-islet origin of pancreatic islet cell tumors.

Authors:  Alexander O Vortmeyer; Steve Huang; Irina Lubensky; Zhengping Zhuang
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

9.  Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study.

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

Review 10.  Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.

Authors:  Fathia Gibril; Michael Schumann; Andrea Pace; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

View more
  20 in total

1.  Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 2.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

3.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

4.  Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience.

Authors:  Friederike Eisner; Diana Hermann; Khaled Bajaeifer; Jörg Glatzle; Alfred Königsrainer; Markus A Küper
Journal:  Visc Med       Date:  2017-06-16

5.  Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression.

Authors:  Brian P Riff; David A Leiman; Bonita Bennett; Douglas L Fraker; David C Metz
Journal:  Pancreas       Date:  2016-02       Impact factor: 3.327

Review 6.  Gut homeostasis, injury, and healing: New therapeutic targets.

Authors:  Sema Oncel; Marc D Basson
Journal:  World J Gastroenterol       Date:  2022-05-07       Impact factor: 5.374

Review 7.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

Review 8.  Zollinger-Ellison syndrome: recent advances and controversies.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

Review 9.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

10.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.